Cinda Biotech announced that in the third quarter of 2025, the company obtained total product revenue exceeding RMB 3.3 billion, an increase of about 40% over the previous year. The field of oncology treatment maintains a leading position, with significant product portfolio advantages. Major products such as Daboshu have grown steadily, and the revenue share of innovative products has further increased. The potential of the integrated product line was rapidly unleashed, and the market entry and channel marketing efforts of Xinermei, Cipilac and Xinbimin achieved remarkable results, product volume accelerated, and revenue contributions expanded significantly.

Cinda Biotech announced that in the third quarter of 2025, the company obtained total product revenue exceeding RMB 3.3 billion, an increase of about 40% over the previous year. The field of oncology treatment maintains a leading position, with significant product portfolio advantages. Major products such as Daboshu have grown steadily, and the revenue share of innovative products has further increased. The potential of the integrated product line was rapidly unleashed, and the market entry and channel marketing efforts of Xinermei, Cipilac and Xinbimin achieved remarkable results, product volume accelerated, and revenue contributions expanded significantly.